Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Disc Medicine (NASDAQ:IRON) announced that John Quisel, J.D., Ph.D., President and Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 3:00 pm PT / 6:00 pm ET. A live webcast will be available via the company's investor relations website at ir.discmedicine.com, and an archived replay will be posted after the event.

Key Figures

Conference edition 44th Annual J.P. Morgan Healthcare Conference

Presentation date January 14 Conference corporate presentation date

Presentation time PT 3:00 pm PT Scheduled conference presentation time

Presentation time ET 6:00 pm ET Scheduled conference presentation time

Market Reality Check

$79.29 Last Close

Volume Volume 604,195 vs 20-day average 671,620 (relative volume 0.9x). normal

Technical Price 77.36 is trading above 200-day MA of 63.64.

Peers on Argus

IRON was down 1.62% pre-news while close peers showed mixed moves: AGIO up 0.48%, TARS nearly flat at -0.04%, with ARQT, TVTX, and OCUL down between about -2.5% and -5.2%. This pattern suggests the move was more stock-specific than a broad sector swing.

Historical Context

Date	Event	Sentiment	Move	Catalyst
Nov 06	Earnings and update	Positive	-1.5%	Q3 2025 results, NDA submission for bitopertin, runway extended into 2029.
Nov 03	Clinical data preview	Neutral	-1.8%	Announcement of upcoming ASH Phase 2 data presentations for DISC-0974 and DISC-3405.
Oct 31	Investor conferences	Neutral	+0.6%	Participation in multiple November 2025 investor conferences with webcast access.
Oct 21	Upsized equity offering	Negative	-1.1%	Pricing of $250M upsized public offering of common stock and pre-funded warrants.
Oct 20	Proposed equity offering	Negative	-3.1%	Announcement of proposed $220M common stock and pre-funded warrant offering.

Pattern Detected

Equity financings have tended to see modest negative reactions, while clinical and conference updates often draw only mild moves regardless of generally constructive business progress.

Recent Company History

Over the past few months, Disc Medicine reported Q3 2025 results and an NDA submission for bitopertin in EPP on September 29, 2025, alongside cash of $615.9M and a runway into 2029. The company highlighted upcoming Phase 2 data for DISC‑0974 and DISC‑3405 and initiated additional studies. In October 2025, Disc executed a sizable upsized public offering, followed by multiple insider Form 4 sales. Conference participation and ASH presentations reinforced visibility. Today’s J.P. Morgan conference presentation fits this pattern of ongoing investor outreach and pipeline communication.

Market Pulse Summary

This announcement highlights Disc Medicine’s plan to deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14 at 3:00 pm PT/6:00 pm ET, with a webcast and replay available. Investors can use this event to track updates on the hematology pipeline and commercialization plans following the recent NDA submission for bitopertin and the late 2025 equity financings. Key items to watch include development timelines, capital allocation priorities, and any changes to strategic outlook.

Key Terms

clinical-stage medical

"a clinical-stage biopharmaceutical company focused on the discovery, development"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

hematologic medical

"treatments for patients suffering from serious hematologic diseases, announced today"

Hematologic describes anything related to blood, the organs that make blood, or diseases affecting blood components such as red and white blood cells, platelets, or bone marrow. Investors pay attention because hematologic conditions create specific markets for drugs, tests and procedures, with unique clinical trial paths, regulatory hurdles and revenue potential — like a distinct product category that can shape a healthcare company’s sales and risk profile.

webcast technical

"A live webcast of the presentation will be available through the investor"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

WATERTOWN, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that John Quisel, J.D., Ph.D., President and Chief Executive Officer, will give a corporate presentation at the 44^th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14^th at 3:00 pm PT / 6:00 pm ET.

A live webcast of the presentation will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Media Contact

Peg Rusconi
Deerfield Group
peg.rusconi@deerfieldgroup.com

Investor Relations Contact

Christina Tartaglia
Precision AQ
christina.tartaglia@precisionaq.com

FAQ

When will Disc Medicine (NASDAQ:IRON) present at the J.P. Morgan Healthcare Conference?

Disc Medicine will present on January 14, 2026 at 3:00 pm PT / 6:00 pm ET.

Who will speak for Disc Medicine (NASDAQ:IRON) at the January 14, 2026 presentation?

John Quisel, J.D., Ph.D., President and Chief Executive Officer, will give the corporate presentation.

How can investors watch Disc Medicine's (NASDAQ:IRON) J.P. Morgan presentation live?

A live webcast will be available through the investor relations section at ir.discmedicine.com.

Will Disc Medicine (NASDAQ:IRON) provide a replay of the J.P. Morgan presentation?

Yes. An archived replay will be available on the company's investor relations website after the event.

What topics will Disc Medicine (NASDAQ:IRON) cover in the January 14, 2026 presentation?

The company said the presentation will cover corporate updates and recent developments relevant to investors.

Where can I find the webcast link for Disc Medicine's (NASDAQ:IRON) J.P. Morgan presentation?

The webcast link will be posted in the investor relations section of the company's website at ir.discmedicine.com.